Sarepta Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 7, 2024 and accepted by EDGAR at Aug 7, 2024, 16:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $360.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $720.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $138.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $265.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$701.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | $34.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $4.8m | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $9.0m | us-gaap:InterestExpense |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $7.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $12.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $6.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | $42.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $0.07 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | $0.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $0.07 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | $0.45 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 99,144,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 99,129,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$227.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $61.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-06-30 | $383.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $2.68bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $3.42bn | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $688.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $2.35bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $1.23bn | us-gaap:LongTermDebt |
| Current portion of debt | At period end2024-06-30 | $91.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-06-30 | $1.08bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-092720. Last ingested by Listed: Nov 5, 2026, 17:27 ET. Listed shows no prices and gives no investment advice.